. Adeno-associated virus mediated gene delivery into coronary microvessels of chronically instrumented dogs.
infectious units. Dogs were followed for 2 (n ϭ 4) or 4 wk (n ϭ 6). Hemodynamics or body weight did not change. In LV tissue slices, a fluorescein-labeled antibody to GFP stained endothelial and smooth muscle cells but was absent in myocytes. To quantify transduction, slices were then stained with antibodies against ␣-smooth muscle actin or von Willebrand factor. Approximately 4% of arterioles and 2% of microvessels stained positive for anti-GFP independent from viral titer or duration. By regression analyses, the percent of vessels transfected was proportional to the increase in LV systolic pressure during occlusion. AAV is a potential vector for gene transfer into the coronary microcirculation in large animals, including perhaps humans. white cells; hemodynamics; green fluorescent protein; von Willebrand factor THE ENDOTHELIAL CELL LAYER plays a key role in maintaining vascular homeostasis by regulating vasomotion, leukocyte adherence, platelet activation, thrombosis, and vascular inflammation (24) . In the coronary circulation, microvascular endothelial dysfunction underlies and limits vascular function in hypertension (4), diabetes (16) , and heart failure (4) and predicts a poor prognosis in patients with coronary heart disease (22) .
Gene therapy with its potential for long-term correction of changes in protein expression in transduced cells represents a potential approach for treatment of vascular diseases (12) , particularly if methods are developed to transduce microvessels, the site of vascular resistance and exchange, in large animals including humans. The use of adeno-associated viruses (AAV) has many advantages. Wild-type AAV infection does not produce any symptoms in humans (2) . Gene expression in skeletal muscle after AAV-mediated gene transfer has been demonstrated for up to a year in mice (11, 27) and dogs (8) , indicating the potential use of AAV for long-term effective gene transfer.
Arterial gene transfer using AAV vectors has been demonstrated in normal rats (1, 6, 19) , rabbits (18) , and hypercholesterolemic monkeys (13) . Although providing proof of principle, these studies applied vascular occlusion of 20-to 60-min duration to arrest blood flow and to provide a greater time to incubate the vessels with the vector, which, in the coronary circulation, is hardly feasible as a clinical approach. Kaplitt et al. (9) reported a small portion of transduced cardiomyocytes after intracoronary administration of AAV; however, that study did not determine the extent of coronary microvascular transduction. This is important because at least part of the cardiac dysfunction occurring in many cardiac diseases may be attributed to microcirculatory dysfunction including altered eNOS gene expression, and a number of therapies directed toward correcting coronary vascular dysfunction are effective in the treatment of heart disease.
The adequate mixing of viral particles used therapeutically on injection into the flowing blood, arterial or venous, is likely to result in a more even distribution of particles especially to blood vessels compared with intramyocardial injection. This is particularly true if the gene to be used encodes for a diffusible substance such as a local hormone, i.e., nitric oxide, which itself diffuses to adjacent cells. Endothelial cells produce a number of substances such as nitric oxide or prostaglandins that can diffuse over some distance and whose production may be decreased during disease states. With this in mind and to develop methods in large animals to address the potential mechanisms and therapies needed to correct endothelial coronary dysfunction in humans, we assessed the potential of AAV to transfer a gene into the coronary microvasculature after direct injection of the vector into the arterial circulation. This study was designed to respond to the call (14) to extend studies in small animals, particularly mice and rats, to large animal models to develop methods potentially applicable to treatment of humans. These sentiments were also expressed in an editorial (7) indicating that making the connections between basic investigative studies and gene therapy remains to be done. Studies in rodents need to be extended to large-animal models.
To demonstrate successful transduction of coronary microvessels, the vector was designed to encode for green fluorescent protein (GFP). This is important because the endothelium is the first structure encountered by a virus particle after intra-arterial or intravenous injection. In addition, because endothelial dysfunction is characteristic or pathonomic for many cardiovascular diseases, the endothelium may be an ideal target for gene transfer.
METHODS
The protocols were approved by the Institutional Animal Care and Use and Biosafety Committees of the New York Medical College and conform to the Guiding Principles for the Care and Use of Animals published by the National Institutes of Health and the American Physiological Society.
Surgical procedure and instrumentation. Ten male mongrel dogs were anesthetized (25 mg/kg iv pentobarbital sodium) and instrumented with fluid-filled catheters in the left atrium and aorta, with a hydraulic occluder around the ascending aorta, and for measurement of left ventricular (LV) pressure and left circumflex coronary artery blood flow as described previously (21, 25) . Dogs were allowed to recover for 10-14 days and trained to lie quietly on the laboratory table.
AAV preparation. Recombinant AAV type 2 with a cytomegalus virus enhancer/chicken ␤-actin promoter, encoding for GFP, was generated and purified as reported previously (5, 28, 29) . AAV was suspended in 1 ml of phosphate buffer, stored at Ϫ70°C, and thawed immediately before use.
Experimental protocols. The dogs were weighed, body temperature was measured, and a venous blood sample was taken from a foreleg. Baseline hemodynamics were measured while the animal was lying quietly on the laboratory table, followed by anesthesia (pentobarbital, 25 mg/kg iv) and intubation. The dog was ventilated (Harvard Instruments) at a positive end-expiratory pressure of 7 cmH 2O for 30 min by using a water bottle containing 1% bleach to destroy all exhaled virus. The aortic constrictor was inflated to raise LV pressure by ϳ50 mmHg for 5-10 min. At steady state, the virus suspension was injected into the left atrial catheter as a bolus. The dog was kept in a separate cage for 24 h, after which feces, urine, and the cage were thoroughly disinfected with bleach. Four animals received a virus concentration of 10 10 infectious units (iu) and were followed for 14 days; six animals received a virus concentration of either 10 10 (n ϭ 3) or 10 12 iu (n ϭ 3) and were followed for 28 days. Body temperature and weight were monitored daily, and venous blood sampling and hemodynamic measurements were repeated at days 3, 7, 14, 21 , and 28. The animals were killed with an overdose of pentobarbital (60 mg/kg), and LV tissue samples (1 cm 3 ) were stored in either liquid nitrogen or phosphate-buffered formalin solution (10%).
Immunohistochemistry. Frozen LV tissue sections were fixed in 3.7% formaldehyde. Fluorescence of anti-GFP anti- Values are means Ϯ SE. HR, heart rate; LVPmax, maximal left ventricular pressure; LVPed, end-diastolic left ventricular pressure; dP/dtmax, maximal change in pressure over time; CBFmean, mean coronary blood flow; AOPmean, mean aortic pressure; PB, pentobarbital sodium; AOC, constriction of the aorta. * P Ͻ 0.05 compared with day 0. body was detected by confocal laser microscopy (MRC-1000, Bio-Rad) with an optical section thickness of 0.57 m. The green fluorescence of GFP was detected but not used for quantitation because of potential nonspecific tissue autofluorescence. For additional analyses, samples of myocardium were fixed in 10% phosphate-buffered formalin and embedded in paraffin. Sections 4 m thick were deparaffinized and heated in a microwave oven in 10 mM citric buffer, pH 6.0. Subsequently, GFP was stained with goat anti-GFP (Rockland), nuclei with propidium iodide (10 mg/ml), smooth muscle cells with mouse anti-␣-smooth muscle actin (clone 1A4, Sigma Chemical), endothelial cells with rabbit polyclonal anti-human von Willebrand factor (vWF; Sigma Chemical), and myocytes with mouse monoclonal anti-␣-sarcomeric actin (clone 5C5, Sigma Chemical). To quantify GFP expression, two or three paraffin-embedded LV tissue sections per sample were stained with anti-GFP and either anti-␣-smooth muscle actin as an indicator of arterioles, or anti-human vWF as an indicative of microvessels. The number of arterioles antibody-positive for GFP was divided by the number of arterioles counted (the same for microvessels). The number of arterioles sampled was 178 Ϯ 10 per animal; the corresponding value for microvessels was 703 Ϯ 18. Quantification was done by fluorescent microscopy at a magnification of ϫ1,000.
Further LV tissue sections were stained with hematoxylineosin. Tissues were saved from almost all organs in the body, but, because of the extensive time commitment to perform morphometrics on all those tissues, those studies are not included in this report. Statistical analysis. All data are mean values Ϯ SE. Expression of GFP was not different between dogs followed for 2 or 4 wk, or between dogs injected with 10 10 or 10 12 iu of AAV. Therefore, for calculation of transduction efficiency, data from dogs with 10 10 and 10 12 iu of AAV were combined, and data on hemodynamics, body weight, body temperature, and cell counts were pooled among all dogs. Mean values were compared by one-way ANOVA for repeated measurements, followed by Tukey's post hoc test when an overall significance was detected. Linear least squares regression analysis was performed to determine the relationship between percent of vessels transfected and LV systolic pressure during occlusion.
RESULTS
Hemodynamics. During pentobarbital anesthesia, heart rate increased, whereas dP/dt max was reduced (Table 1) . With aortic constriction, LV peak pressure and left circumflex coronary artery blood flow increased. None of the hemodynamics changed significantly during 2-4 wk compared with baseline values before virus administration in the conscious state.
Body weight and temperature. Body weight and temperature remained unchanged during 2-4 wk. For instance, body weight and temperature were 25.9 Ϯ 0.7 kg and 39 Ϯ 0.1°C and 26.0 Ϯ 0.7 kg and 38.6 Ϯ 0.1°C at control and day 28, respectively.
Differential cell counts. Hemoglobin content and the number of red and white blood cells remained unchanged during 2-4 wk ( Table 2 ). The percentage of neutrophils was significantly decreased at days 21 and 28. The percentage of lymphocytes, eosinophils, and monocytes was unchanged. Standard histology. With hematoxylin-eosin staining (not shown), the LV myocardium appeared normal. No white cell infiltration was found.
Distribution of GFP. GFP was detected in vascular structures by an antibody (Figs. 1 and 2 ) but was absent in nonvascular structures, i.e., cardiomyocytes. In blood vessels, the antibody to GFP stained endothelial and smooth muscle cells and to a lesser degree the adventitial layer.
Quantification of GFP. The frequency of transduction of antibody-positive GFP was ϳ4% (range: 1.0-11.5%) in arterioles (Fig. 3) and 2% (range: 1.3-2.3%) in microvessels (Fig. 4) . Transduction efficiency was not different in samples from LV septum or free wall, with transfection by either 10 10 or 10 12 iu (data not shown), or at 14 or 28 days. There was a correlation between the percent vessels transfected and the LV systolic pressure during occlusion of the aorta (Fig. 5) .
DISCUSSION
We demonstrated for the first time that AAV-mediated gene delivery with a clinically feasible route of administration is able to significantly transduce coronary microvessels in a large animal species without affecting myocardial function or provoking deleterious side effects. This is the first step to answer the challenge (7, 14) to develop methods to bridge the gap between studies in rodents and humans.
Previous studies demonstrating AAV-mediated arterial gene transfer used incubation of clamped carotid artery segments with an AAV suspension, interrupting the bloodstream for 20 (19) , 30 (1, 13, 18) , or 60 (18) min. Whereas such procedure may be performed in the peripheral vasculature or in vein grafts before implantation during bypass surgery, it is clearly not feasible during coronary catheterization. In pigs, intracoronary infusion of an AAV preparation encoding for ␤-galactosidase transduced cardiomyocytes up to 6 mo at a rate of 0.2% (9) . Surprisingly, these authors did not report the extent of transduction of vascular structures; however, the dose of AAV used may have been too low for detectable gene delivery into vascular cells (10 7 -10 8 vs. 10 10 -10 12 iu in the present study). Whereas intramyocardial injection of AAV can transduce cardiomyocytes in rabbits (26) and rats (15), we, after injection of AAV into the atrium, did not observe expression of GFP in cardiomyocytes, even when increasing the dose of AAV from 10 10 to 10 12 iu. We consistently found expression of GFP in endothelial and smooth muscle cells and, although to a lesser degree, in the adventitial layer. It appears that, at a particle size of ϳ20 nm, vascular layers do not represent an anatomical barrier for AAV distribution as was demonstrated for adenoviruses with a particle size of 70-100 nm (20) . This may indicate a considerably higher tropism of AAV, at least the type 2 serotype we used, for endothelial and smooth muscle cells rather than for cardiomyocytes in dogs.
AAV-mediated gene transfer to carotid arteries was reported to transduce all vascular layers in rat (1, 19) but exhibited a preference for smooth cells in rabbits (14) and for microvascular endothelial cells of vasa vasorum in monkeys (13) . In the present study in dogs, we did not observe a preference for either endothelial or smooth muscle cells, further pointing to potential species differences. We demonstrated transduction of ϳ4% of arterioles both at 14 and 28 days after AAV administration, confirming stability of AAV-mediated gene transfer over time. Such transduction rate may already be pathophysiologically relevant, given that the encoded protein would release paracrine mediators that impact on vascular and cardiomyocyte function (17) .
None of the dogs investigated in this study showed any clinical sign of disease, compromised myocardial function, myocardial damage, or inflammatory white cell infiltration in standard histology, in line with previous reports (20) . We observed no change in the lymphocyte fraction in differential blood cell counts at days 21 and 28 after AAV administration, similar to the changes observed after intramuscular administration of AAV in dogs (8) . Indeed, mice after intravenous but not after intramuscular delivery of AAV encoding for ovalbumin developed cytotoxic lymphocytes against ovalbumin (3) .
The method we used to administer AAV was taken from studies validating the distribution of radioactive microspheres in the coronary circulation in the 1970s (21) . This method takes advantage of the mixing in the left atrium and left ventricle before expulsion into the aorta and distribution into the coronary circulation. Additionally, partial occlusion of the aorta serves to increase coronary blood flow, as we found, via metabolic dilation and increased perfusion pressure. There was a linear relationship between LV systolic pressure during occlusion and transduction, suggesting that partial occlusion of the aorta facilitates transfection of coronary microvessels. Finally, anesthetizing and ventilating the dog into a bottle containing bleach eliminates the possibility that the vector will be exhaled to endanger laboratory workers, regardless of the infectivity. These precautions may not have been necessary under the conditions of our study, but similar precautions may be needed in the future if the gene contained within the AAV has activity in humans. Lastly, counterpulsation techniques and balloon catheters, depending on the state of contractile function, could be used to "direct" virus into the coronary circulation in humans. Although the number of endothelial cells positive for anti-GFP seems small, a few percent, the production of the gene product may be much higher. This could be altered by changing the promoter and by designing strategies for incorporation of multiple copies of the gene in the same endothelial cell.
The 2-4% of microvessels transduced after injection of AAV containing GFP may seem like a small number; however, there are literally millions of microvessels, a difficult number to calculate, in each heart. If we assume that all the blood vessels are represented by the length of the capillaries (an underestimate), then we can calculate the total capillary length in an average 72-g LV free wall. From previous studies, we have found that there are 3,011 capillaries/mm 2 dog heart. If we assume that each capillary is 1 mm long, then this results in 3,011 mm of capillary/mm 3 dog tissue. Times 1,000 mm 3 /cm 3 , this equals 3,011,000 mm capillary/ cm 3 dog heart. If dog tissue has a density of 1.06 g/cm 3 , then a 72-g dog LV free wall has a volume of 67.9 cm 3 . 3,011,000 mm capillary/cm 3 ϫ 67.9 cm 3 ϭ 204,446,900 mm capillary/dog heart. If we take an average 3% transduction, then 0.03 times 204,446,900 equals 6,133,407 mm capillary were infected by the virus and expressed GFP. We injected 10 10 particles (the injection of 10 12 did not increase the infection-expression index), and 10% of cardiac output goes to the coronary circulation (excluding recirculation). Then a total of 10 9 particles went through the coronary circulation to get 6 ϫ 10 6 mm capillary transduced. This indicates that millions of blood vessels were transduced. Furthermore, because more than one virus particle may have infected each cell (which we cannot determine), because other cell types expressed the GFP (i.e., smooth muscle and white blood cells), and because not all the cells containing GFP may have been measured (the transduction rate unknown), the actual number of cells transfected after our injection of AAV is undoubtedly even greater than six million. Finally, it should be remembered that each cardiac myocyte is surrounded by three capillaries, located at the angles of an equilateral triangle, so that infection of only one in three capillaries would be needed to influence all the cardiac myocytes.
Because of the potential problem of nonspecific tissue autofluorescence when using the fluorescence properties of GFP, we used an antibody to GFP to quantitate the expression of GFP. Using these techniques, we found staining in blood vessels and not in cardiac myocytes. These conclusions would not have been different when the fluorescence of GFP was used because the nonspecific fluorescence would if anything lead to an overestimate of GFP expression.
In conclusion, we demonstrated AAV-mediated gene transfer to the coronary microcirculation in dogs using a clinically relevant route of administration and a clinically relevant vector. AAV-mediated gene transfer may prove to be a valuable tool to study coronary pathophysiology in a large animal species relevant for human disease. Furthermore, depending on the gene to be transferred, the promoter to be used, the biological and therapeutic properties of the gene product, and the number of copies of the gene expressed in each cell, our data indicate that blood vessels may be a therapeutic target in disease states associated with endothelial dysfunction.
